Better Stem Cell Therapies? PODS-Enhanced Organoids

A new study led by researchers at the University of Glasgow presents compelling evidence of PODS ability to elevate organoid-based therapies to a new level.
Mononuclear phagocytic cells such as monocytes, macrophages and dendritic cells are at the vanguard of our immune system. Harnessing the capabilities of these cells has tremendous potential for fighting disease.
Rather than reprogramming at the level of DNA or RNA, researchers are now using PODS® sustained-release proteins to efficiently reprogram the proteome directly. With 70% of cells reprogrammed in 24 hours, no expansion is needed.
Whether you are developing new therapies or simply delving into the mechanisms of the immune system, PODS® can help you with your quest.